Chronic migraine: Efficacy and safety of CGRP slightly better than botulinum toxin

Key clinical point: Calcitonin gene-related peptide (CGRP) monoclonal antibody was superior to botulinum toxin in reducing the frequency of acute analgesic intake in patients with chronic migraine (CM). Treatment-related serious adverse events (SAEs) were lower with CGRP monoclonal antibody.

Major finding: CGRP monoclonal antibody was superior to botulinum toxin in reducing the frequency of acute analgesics intake (weighted mean difference, −1.31; P = .02113). Treatment-related SAEs were lower with CGRP monoclonal antibody vs. botulinum toxin (relative risk, 0.505; P = .001).

Study details: Findings are from a meta-analysis of 10 studies including 6,325 patients, which performed indirect treatment comparison between CGRP monoclonal antibody and botulinum toxin for prophylactic treatment of CM.

Disclosures: No information on funding was available. The authors declared no conflicts of interest.

Source: Lu J et al. Front Pharmacol. 2021 May 3. doi: 10.3389/fphar.2021.631204.

Key clinical point: Calcitonin gene-related peptide (CGRP) monoclonal antibody was superior to botulinum toxin in reducing the frequency of acute analgesic intake in patients with chronic migraine (CM). Treatment-related serious adverse events (SAEs) were lower with CGRP monoclonal antibody.

Major finding: CGRP monoclonal antibody was superior to botulinum toxin in reducing the frequency of acute analgesics intake (weighted mean difference, −1.31; P = .02113). Treatment-related SAEs were lower with CGRP monoclonal antibody vs. botulinum toxin (relative risk, 0.505; P = .001).

Study details: Findings are from a meta-analysis of 10 studies including 6,325 patients, which performed indirect treatment comparison between CGRP monoclonal antibody and botulinum toxin for prophylactic treatment of CM.

Disclosures: No information on funding was available. The authors declared no conflicts of interest.

Source: Lu J et al. Front Pharmacol. 2021 May 3. doi: 10.3389/fphar.2021.631204.

Key clinical point: Calcitonin gene-related peptide (CGRP) monoclonal antibody was superior to botulinum toxin in reducing the frequency of acute analgesic intake in patients with chronic migraine (CM). Treatment-related serious adverse events (SAEs) were lower with CGRP monoclonal antibody.

Major finding: CGRP monoclonal antibody was superior to botulinum toxin in reducing the frequency of acute analgesics intake (weighted mean difference, −1.31; P = .02113). Treatment-related SAEs were lower with CGRP monoclonal antibody vs. botulinum toxin (relative risk, 0.505; P = .001).

Study details: Findings are from a meta-analysis of 10 studies including 6,325 patients, which performed indirect treatment comparison between CGRP monoclonal antibody and botulinum toxin for prophylactic treatment of CM.

Disclosures: No information on funding was available. The authors declared no conflicts of interest.

Source: Lu J et al. Front Pharmacol. 2021 May 3. doi: 10.3389/fphar.2021.631204.